APP and Alzheimer disease: Aβ and amyloidogenic APP metabolites are normally trafficked to lysosomes for degradation, and as lysosomal efficiency declines with aging and AD, the substrates accumulate within lysosomes and lipofuscin-related organelles [47, 70].